Cover Image
市場調查報告書

復發惡化型多發性硬化症 (SPMS):開發中產品分析

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255981
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
復發惡化型多發性硬化症 (SPMS):開發中產品分析 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 123 Pages
簡介

復發緩解型變化為無法再緩解的時候,該疾病就會演變成復發惡化型。其症狀有四肢無力感、腳部肌肉的發硬與緊張、腸道和膀胱的障礙、強烈的疲勞、沮喪、認知障礙等。

本報告提供復發惡化型多發性硬化症治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

復發惡化型多發性硬化症 (SPMS) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • AB Science SA
  • Actelion Ltd
  • Biogen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Immune Response BioPharma, Inc.
  • Innate Immunotherapeutics Ltd
  • 杏林藥業
  • Mallinckrodt Plc
  • MedDay SA
  • MedImmune, LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Novartis AG
  • Opexa Therapeutics, Inc.
  • Xenetic Biosciences (UK) Limited

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

最近的開發平台趨勢

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8260IDB

Summary

Global Markets Direct's, 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
  • The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects
  • The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Secondary Progressive Multiple Sclerosis (SPMS) Overview
  • Therapeutics Development
    • Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview
  • Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies
  • Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Actelion Ltd
    • Biogen, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genzyme Corporation
    • Glialogix, Inc.
    • Immune Response BioPharma, Inc.
    • Innate Immunotherapeutics Ltd
    • Kyorin Pharmaceutical Co., Ltd.
    • Mallinckrodt Plc
    • MedDay SA
    • MedImmune, LLC
    • Merck KGaA
    • Meta-IQ ApS
    • Novartis AG
    • Opexa Therapeutics, Inc.
    • Xenetic Biosciences (UK) Limited
  • Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • 7Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • biotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DC-TAB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etomoxir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLX-1112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-402668 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-MS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imilecleucel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon beta-1b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-2736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methoxsalen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIS-416 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • opicinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Xemys - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects
  • Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products
  • Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones
    • Featured News & Press Releases
      • May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial
      • Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN
      • Apr 13, 2016: Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners
      • Apr 01, 2016: PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys for Multiple Sclerosis
      • Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis
      • Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003
      • Oct 07, 2015: MedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis
      • Oct 06, 2015: Opexa Announces Granting of New T-cell Patents Covering Tcelna; Patent Estate Increases to 160 Issued Patents
      • Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner
      • Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting
      • Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC
      • Oct 07, 2014: Update on Innate's Phase 2B trial and other recent activities
      • Aug 19, 2014: Innate's Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval
      • Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis
      • Jun 18, 2014: Compassionate Use Programme Update
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science SA, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Actelion Ltd, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen, Inc., H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Glialogix, Inc., H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Immunotherapeutics Ltd, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Mallinckrodt Plc, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay SA, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedImmune, LLC, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Merck KGaA, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Meta-IQ ApS, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects, H2 2016
  • Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top